News Briefs


Unitech Medical debuts 2 new CamWell moisturizers

CamWell lotion

Unitech Medical, a women-owned small family business based in Minnesota, is introducing Innovative CamWell Hand to Heal and Herb to Soothe botanical moisturizers.

The company noted that the products have clinically proven in-formula clinical benefits for painful, itchy and cracked bleeding skin, according to the company.

Additionally, the products have the following attributes: vegan, gluten free, cruelty free, nut oil free, no harsh chemicals, paraben free, BPA free, sustainable ingredients, recyclable packaging and made in the USA.

CamWell products come in unique, purposeful packaging that serves a multitude of functions, including being aesthetically pleasing/draws the eye, educates the customer on product and amazing benefits, and makes natural CamWell products easily giftable!


CareSens N to partner with American Diabetes Association at Step Out: Southern California

For the second year, CareSens N is partnering with the American Diabetes Association to support the diabetes community in Southern California. 

Step Out Walk to Stop Diabetes (Step Out) is the signature fundraising walk of the ADA. The events are back in person this year. For more than 30 years, funds raised through these nationwide events have supported educational programming, advocacy efforts and advancements in diabetes research for the over 37 million Americans living with diabetes.

On Sept. 17 at Griffith Park in Los Angeles, CareSens N will participate at the Know Your Numbers booth to help participants of Step Out learn what blood glucose (blood sugar) numbers represent and how lowering those numbers will help them successfully manage their diabetes.


Delimex brings Mexican street flavors to the frozen aisle

Delimex taquitos

Delimex, a Kraft Heinz brand, is redefining the frozen aisle this summer with refreshed packaging, enhanced flavor and nearly double the taquito filling in its frozen product.

The company shared that with the frozen snack category being a $6 billion category and Mexican inspired snacks being a large amount of that growth, the brand listened to its fans and made changes to inspire authenticity. Beginning this month, it is debuting refreshed packaging, enhanced flavor and nearly double the taquito filling for the perfectly balanced bite of crispy, savory tortilla to filling ratio, the brand said.

As a brand we are all about bringing bold, delicious flavor to life’s dullest moments,” said Rachel Drof, director of brand communications at Delimex. “We are excited for fans to try our new and improved product and experience the golden crispy shell, melty cheese and shredded meat, giving your senses a moment to come alive — and don’t forget all the cool toppings you dip your taquito into!”

With fresh, authentic Mexican street flavors rolled up into crunchy taquitos that are ready to eat in two microwaveable minutes, Delimex taquitos bring flavor to your mealtime, no matter if it’s a snack, mini-meal or the main event.

Delimex, a combination of delicious and Mexican, was founded by a Mexican-born entrepreneur who brought hand-held Mexican street food to main street. Refreshed Delimex products include:

  • Beef Corn Taquitos;
  • Chicken Corn Taquitos;
  • Chicken and Cheese Flour Taquitos;
  • Beef and Cheese Flour Taquitos; and
  • Beef and Cheddar Rolled Tacos.

To celebrate its Mexican heritage and the refresh, Delimex partnered with two authentic muralists, Ale Ballesteros and Raul Urias, to create two murals in Dallas and Baltimore. The murals highlight various styles, with Dallas featuring beautiful Alejibres — Mexican Spirit Dogs — and Baltimore showcasing the painted skeleton.

Starting this month, the vibrant new look and feel of Delimex will be rolling out at retailers nationwide including Walmart, Target, Kroger, on Amazon and more. 


RXBAR debuts chocolate cinnamon brownie flavor

Rx bar

RXBAR is launching a new flavor, RXBAR Chocolate Cinnamon Brownie, for a limited time only.

Chocolate Cinnamon Brownie has an indulgent chocolate flavor and features 12 grams of protein, simple ingredients, no added sugar and most importantly, No B.S., the company said.

Containing simple ingredients — including dates, egg whites, almonds and cashews — Chocolate Cinnamon Brownie is a decadent, limited-time addition to the RXBAR portfolio to offer fans more taste variety. With crunchy whole almonds, deliciously rich chocolate chunks and fragrant cinnamon spice, the bar nods to the nostalgic senses of homemade brownies from the oven.

"RXBAR consumers seek variety, so we're constantly innovating to deliver delicious new flavors made with only simple ingredients," said Eileen Flaherty, senior brand manager, RXBAR. "Adding Chocolate Cinnamon Brownie to our portfolio of No B.S. bars allows us to surprise and delight our fans, while offering them something new to enjoy for a limited time."

The new RXBAR Chocolate Cinnamon Brownie is available now through December at and select retailers nationwide.


Lilly intros citrate-free Taltz

generic vials teaser

Eli Lilly is unveiling a new, citrate-free formulation of Taltz (ixekizumab) injection 80 mg/ml.

The new formulation, approved by the Food and Drug Administration in May, includes the same active ingredient as the original formulation. The new formulation significantly reduces injection site pain experienced by some people immediately following injection as shown by an 86% decrease in a visual analog scale of pain versus the original formulation, the company said.

Taltz is approved to treat adults and children 6 years old and older with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy, adults with active psoriatic arthritis, active ankylosing spondylitis and active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation. 

“Taltz has long delivered effective treatment with a well-established safety profile that addresses symptoms for people living with plaque psoriasis, psoriatic arthritis, AS and nr-axSpA,” said Ashley Diaz-Granados, vice president of U.S. Immunology at Lilly.

“We’re proud of our investment in research that keeps the patient experience at the center. This new formulation provides yet another reason to choose Taltz, and we look forward to introducing it to patients who have not yet tried Taltz and providing a seamless transition for those already enjoying the medicine’s benefits,” she said. 

“Today is an exciting milestone for the nearly 30 million people around the world who live with the challenging symptoms of these autoimmune diseases that affect the skin and joints,” said April Armstrong, professor of dermatology and associate dean of clinical research at the Keck School of Medicine at the University of Southern California.

“In my six years of prescribing Taltz, I’ve seen firsthand the significant impact Taltz has had for patients across multiple indications,” she said. “The availability of Taltz as a citrate-free formulation represents an important advance in patient care that will allow more patients to experience less injection-site pain.”  


Myovant Sciences, Pfizer gain FDA approval for new indication of Myfembree

The FDA building

Myovant Sciences and Pfizer have obtained the Food and Drug Administration’s blessing for Myfembree (relugolix 40 mg, estradiol 1 mg and norethindrone acetate 0.5 mg) as a one-pill, once-a-day therapy for the management of moderate to severe pain associated with endometriosis in pre-menopausal women, with a treatment duration of up to 24 months.

Myfembree also is approved for heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Myovant Sciences and Pfizer will continue to jointly commercialize Myfembree in the United States, with the product available immediately.

“Endometriosis is a painful, chronic disease with limited therapies to manage symptoms,” said Juan Camilo Arjona Ferreira, chief medical officer of Myovant Sciences.

“The new Myfembree indication helps advance our mission to redefine care for women by helping address a disease with high unmet need, giving women and physicians a new meaningful treatment option to manage moderate to severe pain associated with endometriosis,” he said.

“This approval is an important milestone reflecting Pfizer and Myovant’s commitment to women’s health in areas of significant unmet need,” said James Rusnak, senior vice president, chief development officer, internal medicine and hospital, global product development at Pfizer. “We look forward to making Myfembree available to women with endometriosis and broadening their options in managing this complex disorder.”